Microtia Clinical Trial
— AUR-201Official title:
Long-Term Follow-Up Study of Unilateral Microtia Patients Who Participated in Study AUR 201 05 and Had the AUR-201 Implant in Place at Final Visit (24 Weeks After the First Implantation Surgery)
Long-term follow-up of unilateral microtia patients implanted with AUR-201.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | June 2026 |
Est. primary completion date | June 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 29 Years |
Eligibility | Inclusion Criteria: 1. Participated in Study AUR-201-05 and had the AUR-201 implant (auricle* or auricle and wedge) in place at the Final Study Visit of Study AUR-201-05 (24 weeks after the first implantation surgery). *If the Principal Investigator (PI) opted not to implant the wedge component beneath the auricle component and the subject has only the auricle in place at the Final Study Visit of Study AUR-201-05, the subject will be considered eligible under this inclusion criterion; 2. Subject or guardian signed the informed consent form (ICF). Exclusion Criteria: 1. Any condition which, in the opinion of the PI, places the subject at unacceptable risk if he/she were to participate in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Romo Plastic Surgery | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Auregen Biotherapeutics, SA |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Appearance/Long-Term Durability of the AUR-201 Implant | - The primary efficacy endpoint for the assessment of long-term durability is based on the improvement in overall appearance at 48 and 96 weeks post-implantation compared to pre-implantation baseline as determined by review and rating of photographs on a 5-point Likert scale by a panel of blinded independent experts. | 72 weeks. The study starts at 24 weeks post implantation and ends at 96 weeks post implantation for a total of 72 weeks for this study. | |
Primary | Incidence of Long Term Treatment-Emergent Adverse Events | The primary safety endpoint for the assessment of long-term safety and tolerability is based on the incidence of treatment-emergent adverse events that initiate or worsen after the Final Study Visit of Study AUR-201-05 (24 weeks post-implantation) through the Final Study Visit of this LTFU study (96 weeks post-implantation). Any untoward medical occurrence that initiates or worsens after the Final Study Visit of Study AUR-201-05 through the Final Study Visit of this study (Study AUR-201-06), whether or not considered related to AUR-201 (including the associated procedures, i.e., biopsy, implantation, and explantation), will be included as part of this end.
The severity of AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
72 weeks. The study starts at 24 weeks post implantation and ends at 96 weeks post implantation for a total of 72 weeks for this study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05288790 -
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
|
Phase 2 | |
Recruiting |
NCT05963659 -
Nitrate Modulates Cognitive Impairment Via Oral Microbiota.
|
N/A | |
Completed |
NCT04130321 -
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
|
N/A | |
Recruiting |
NCT05929976 -
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
|
||
Withdrawn |
NCT04230746 -
Effect of Antibiotics on Urinary Microbiome
|
Early Phase 1 | |
Active, not recruiting |
NCT06289283 -
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
|
||
Recruiting |
NCT05714566 -
Research on Gut Microbiome and Metabolomics Alterations in C.Difficile Infected IBD Patients
|
||
Enrolling by invitation |
NCT06225336 -
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)
|
Phase 1 | |
Recruiting |
NCT05068362 -
Auricular Reconstruction in Microtia by Medpor Implant Following Tissue Expansion
|
N/A | |
Completed |
NCT02224677 -
Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)
|
||
Not yet recruiting |
NCT05615116 -
Clinical Study on the Distribution of Digestive Tract Microbiota Before and After Ileocecal Resection in Crohn's Disease
|
||
Enrolling by invitation |
NCT06220994 -
the Gut Microbiome and Metabolomics in Chronic Lower extreMities Threatening Ischemia
|
||
Completed |
NCT00958802 -
Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies
|
Phase 0 | |
Recruiting |
NCT06087874 -
Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice
|
Phase 2 | |
Suspended |
NCT03624608 -
Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures
|
N/A | |
Not yet recruiting |
NCT06394687 -
The Digestion of Protein Powders in Healthy Participants Using SIMBA and LIMBA Capsule
|
N/A | |
Completed |
NCT05417360 -
Akkermansia and Weight Maintenance
|
N/A | |
Recruiting |
NCT02518035 -
Silicone Gel to Improve Scar in Microtia Patients
|
Phase 4 | |
Recruiting |
NCT06072040 -
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03729427 -
Rib Microtia and the Erector Spinae Plane (ESP) Block
|
N/A |